DE69429299D1 - Verwendung von Tachykinin-Antagonisten zur Behandlung von Erbrechen - Google Patents

Verwendung von Tachykinin-Antagonisten zur Behandlung von Erbrechen

Info

Publication number
DE69429299D1
DE69429299D1 DE69429299T DE69429299T DE69429299D1 DE 69429299 D1 DE69429299 D1 DE 69429299D1 DE 69429299 T DE69429299 T DE 69429299T DE 69429299 T DE69429299 T DE 69429299T DE 69429299 D1 DE69429299 D1 DE 69429299D1
Authority
DE
Germany
Prior art keywords
tachykinin antagonists
antagonists
treat vomiting
vomiting
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69429299T
Other languages
English (en)
Other versions
DE69429299T2 (de
Inventor
Russell Michael Hagan
Keith Thomas Bunce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE69429299D1 publication Critical patent/DE69429299D1/de
Publication of DE69429299T2 publication Critical patent/DE69429299T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69429299T 1993-03-19 1994-03-17 Verwendung von Tachykinin-Antagonisten zur Behandlung von Erbrechen Expired - Lifetime DE69429299T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939305718A GB9305718D0 (en) 1993-03-19 1993-03-19 Medicaments

Publications (2)

Publication Number Publication Date
DE69429299D1 true DE69429299D1 (de) 2002-01-17
DE69429299T2 DE69429299T2 (de) 2002-10-17

Family

ID=10732372

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69429299T Expired - Lifetime DE69429299T2 (de) 1993-03-19 1994-03-17 Verwendung von Tachykinin-Antagonisten zur Behandlung von Erbrechen

Country Status (9)

Country Link
US (2) US5547964A (de)
EP (1) EP0615751B1 (de)
JP (2) JPH072658A (de)
AT (1) ATE209909T1 (de)
DE (1) DE69429299T2 (de)
DK (1) DK0615751T3 (de)
ES (1) ES2164684T3 (de)
GB (1) GB9305718D0 (de)
PT (1) PT615751E (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0919245A3 (de) * 1991-09-20 2000-11-15 Glaxo Group Limited NK-1 Rezeptor Antagonist mit einem systemischen antiinflammatorischen Kortikosteroid zur Behandlung von Emesis
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
CA2162400A1 (en) * 1993-05-28 1994-12-08 William M. Snyder Process for preparing and resolving 2-phenyl-3-aminopiperidine
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
DK0780375T3 (da) * 1995-12-21 2002-10-07 Pfizer 3-((5-substitueret benzyl)amino)-2-phenylpiperidiner som substans P-antagonister
JP2000514047A (ja) * 1996-06-26 2000-10-24 ワーナー―ランバート・コンパニー 催吐の処置用医薬の製造のためのタキキニンアンタゴニストの使用
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
CA2352612A1 (en) * 1998-11-27 2000-06-08 Hideo Fukui Pharmaceuticals
NZ501211A (en) * 1999-01-29 2001-10-26 Pfizer Prod Inc Pharmaceutical composition comprising macrolide antibiotic like erythromycin and a Substance P antagonist, and method for treating cancer, bacterial and protozoal infection in non-humans
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
EP1205855A3 (de) * 2000-11-10 2006-01-25 Masae Yanagi Verfahren, System und Vorrichtung zum Verwalten von Daten, Datenhandlungsgerät, Rechnerprogramm und Speichermedium
CA2567342A1 (en) * 2004-06-08 2005-12-22 Travis T. Wager Aza-bicyclo[3.1.0]hex-1-yl derivatives active as nk1 antagonists
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
SG178403A1 (en) * 2009-08-14 2012-03-29 Opko Health Inc Intravenous formulations of neurokinin-1 antagonists
WO2020019247A1 (en) 2018-07-26 2020-01-30 Xw Laboratories, Inc. Compounds as neurokinin-1 receptor antagonists and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048058A (en) * 1975-08-13 1977-09-13 Standard Oil Company (Indiana) Methods to be used in reforming processes employing multi-metallic catalysts
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
FR2610323B1 (fr) * 1987-02-04 1989-06-23 Delalande Sa Enantiomeres de configuration absolue s de derives amide de l'amino-3 quinuclidine, leur procede de preparation et leur application en therapeutique
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
SK284565B6 (sk) * 1991-03-26 2005-06-02 Pfizer Inc. Spôsob prípravy substituovaných piperidínov
DK0589924T3 (da) * 1991-06-20 1996-09-30 Pfizer Fluoralkoxybenzylaminoderivater af nitrogenholdige heterocyclusser
DE69208088T2 (de) * 1991-07-05 1996-11-14 Merck Sharp & Dohme Aromatische verbindungen, diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische anwendung
EP0919245A3 (de) * 1991-09-20 2000-11-15 Glaxo Group Limited NK-1 Rezeptor Antagonist mit einem systemischen antiinflammatorischen Kortikosteroid zur Behandlung von Emesis
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis

Also Published As

Publication number Publication date
EP0615751B1 (de) 2001-12-05
JP2000191522A (ja) 2000-07-11
DE69429299T2 (de) 2002-10-17
JPH072658A (ja) 1995-01-06
US6329394B1 (en) 2001-12-11
ES2164684T3 (es) 2002-03-01
DK0615751T3 (da) 2002-02-18
GB9305718D0 (en) 1993-05-05
US5547964A (en) 1996-08-20
PT615751E (pt) 2002-04-29
ATE209909T1 (de) 2001-12-15
EP0615751A1 (de) 1994-09-21

Similar Documents

Publication Publication Date Title
ATE209909T1 (de) Verwendung von tachykinin-antagonisten zur behandlung von erbrechen
ATE209490T1 (de) Substanz p antagonisten zur behandlung von erbrechen
DE59409832D1 (de) Pflaster zur behandlung von nagelmykosen
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE255896T1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
FI962350A (fi) BPM-12, BMP-13 sekä niiden jännettä indusoivat koostumukset
ATE206757T1 (de) Thrombin sowie verfahren zu seiner herstellung
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE186834T1 (de) Verwendung von wirksamen mengen von aktiven stoffen zur behandlung von mischhaut
ATE315390T1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
ES2058346T3 (es) Compuestos piperidinilicos 1,4-disustituidos.
DE69735482D1 (de) Spiro-azacyclische derivate, deren herstellung und verwendung als tachykinin-antagonisten
DE3851584D1 (de) Gegen Allergie wirkende Benzothiophene und neue und andere ausgewählte Benzothiophene, beide mit Wirkung zur Behandlung von akuten Atmungsangstanzeichen.
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ES2072975T3 (es) Mezcla de esterilizante y metodo de esterilizacion.
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE69004924D1 (de) Therapeutische verwendung von 5-ht3-rezeptor-antagonisten.
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE3586420D1 (de) Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose.
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
DE69131058D1 (de) Verwendung einer therapeutischen Zusammensetzung zur Behandlung von Bronchitis
DE59407576D1 (de) Verwendung von Etofibrat und pharmazeutische Zusammensetzungen, enthaltend Etofibrat, zur Behandlung der diabetischen Angio- und Retinopathie
DE69711422D1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition